Product analysis: the device remains implanted, therefore no product analysis can be performed.Conclusion: without the return of the product, no definitive conclusion can be made regarding the clinical observation.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information that approximately eight years and four months following implant of this transcatheter bioprosthetic pulmonary valve into a patient with a previously implanted homograft (manufacturer unknown) for tetralogy of fallot (tof), the patient reported leg edema, moderate reduced left ventricle function, right ventricle (rv) dilation and reduced systolic function.It was reported that the valve had trivial insufficiency.Approximately a month and a half later, a diagnostic catheterization was performed again revealing post-capillary pulmonary hypertension , rv to pulmonary artery (pa) gradient of 45mmhg with nearly systemic rv pressure, confirmation of reduced left ventricle function, and no relevant atrial shunt.The rv pressure measured 90 mmhg, the pa pressure measured 58 mmhg and the femoral artery pressure measured 100 mmhg.Approximately eight years and seven months following the initial implant of this valve, the valve was re-dilated using a 24 mm non-medtronic balloon.The valve was then replaced with a second transcatheter bioprosthetic pulmonary valve.The replacement valve was post-dilated using a 24 mm non-medtronic balloon.The rv to pa pressure following the replacement valve was 8 mmhg.No additional adverse patient effects were reported.
|